In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS

Where PCSK9 inhibitors can make a difference

Session LDL-cholesterol and secondary prevention of atherosclerotic disease - When less is definitely more!

Speaker Christie Ballantyne

Event : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Lipids
  • Session type : Satellite Symposium
  • Sponsored by Amgen Europe GmbH

This content is currently on FREE ACCESS

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are